The abstract is read at the publisher; the summary is JClub's.
In patients with stage 5 chronic kidney disease, SGLT2 inhibitor use is linked to fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72–0.85).
- Why it matters: Major randomized trials largely excluded stage 5 CKD, leaving limited evidence on whether SGLT2 inhibitors improve cardiovascular and kidney outcomes in this high-risk group.
- What they did: A systematic review through April 10, 2026 pooled random-effects hazard ratios from five observational cohorts (57,156 participants; 28,559 users), with ROBINS-I bias assessment and GRADE certainty.
- The result: SGLT2 inhibitor use is also linked to fewer acute myocardial infarctions (HR 0.64; 95% CI 0.56–0.72), while associations with all-cause mortality (HR 0.84; 95% CI 0.58–1.21) and dialysis initiation (HR 0.63; 95% CI 0.30–1.33) were not statistically significant.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.